Utilization of health care resources in a high-risk medicaid population with chronic obstructive pulmonary disease

P and T

Volumn 31, Issue 5, 2006, Pages 261-268

  Shaya, Fadia T ^a   El Khoury, Antoine C ^b   Samant, Navendu D ^b   Scharf, Steven M ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Department of Pharmaceutical Health Services Research ^*  (United States)

^c University's School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADULT; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE;

EID: 33744930587     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Ward MM, Javitz HS, Smith WM, Bakst A. Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 2000;94(11):1123-1129.
2. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: Results from the Confronting COPD Survey. Respir Med 2003;97(Suppl3):S81-S89.
3. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 2002;96(Suppl C):S3-S10.
4. Carter R, Blevins W, Stocks J, et al. Cost and quality issues related to the management of COPD. Semin Respir Crit Care Med 1999; 20(3):199-212.
5. Division of Epidemiology, National Heart, Lung, and Blood Institute, National Institutes of Health. Data Fact Sheet 2003. Available at: www.nhlbi.nih.gov/health/public/lung/other/copd_fact.pdf. Accessed April 2006.
6. Mapel D, Hurley J, Frost F, et al. Health care utilization in chronic obstructive pulmonary disease: A case-control study in a health maintenance organization. Arch Intern Med 2000;160(17):2653-2658.
7. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study. JAMA 1989;262:907-913.
8. Van Der Molen T, Pieters W, Bellamy D, Taylor R. Measuring the success of treatment for chronic obstructive pulmonary disease patient, physician and health care payer perspective. Respir Med 2002;96(Suppl C):S17-S21.
9. Buist AS. Guidelines for the management of chronic obstructive pulmonary disease. Respir Med 2002;96(Suppl C):S11-S16.
10. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154:954-967.
11. Regueiro CR Hamel MB, Davis RB. A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: Resource intensity, hospital costs, and survival. Am J Med 1998;105:366-372.
12. Halpern MT, Higashi MK, Baskst AW, Schmier JK. The economic-impact of acute exacerbations of chronic bronchitis in the United States and Canada: A literature review. J Managed Care Pharm 2003;9:353-359.
13. Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98(9):883-891.
14. Grasso ME, Weller WE, Shaffer TJ, et al. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:133-138.
15. Cydulka RK, McFaden ER Jr, Everman CL, et al. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary diseases. Am J Respir Crit Care Med 1997;156:1807-1812.
16. Stuart B, Doshi JA, Briesacher B, et al. Impact of prescription coverage on hospital and physician costs: A case study of Medicare beneficiaries with chronic obstructive pulmonary disease. Clin Ther 2004;26(10):1688-1699.
17. Sullivan SD, Ramsye SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S.
18. Molken RV, Postma MJ, Joore MA, et al. Current and future medical cost of asthma and chronic obstructive disease in the Netherlands. Respir Med 1999;93:779-787.
19. Jacobsson L, Hertzman P, Löfdahl CG, et al. The economic impact of asthma and chronic pulmonary disease (COPD) in Sweden, 1980 and 1991. Respir Med 2000;94:247-255.
20. Wouters EFM. Economic analysis of the confronting COPD survey: An overview of results. Respir Med 2003;97 (Suppl 3):S3-S14.
21. Schore J, Brown R, Lavin B. Racial disparities in prescription drug use among dually eligible beneficiaries. Health Care Financing Rev 2004;25(2):78-90.
22. Charlson M, Pompei P, Ales K, MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40(5):373-383.
23. Deyo R, Gherkin D, Ciol M. Adapting a clinical cormorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613-619.
24. Murray CJL, Lopez AD. Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for over 200 Conditions. Cambridge, MA Harvard School of Public Health; 1996.
25. Lenfant C. Morbidity and Mortality: 2000. Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 2000.
26. Gulsvik A. Mortality in and prevalence of chronic obstructive pulmonary disease in different parts of Europe. Monaldi Arch Chest Dis 1999;54:160-162.
27. Mueller RE, Keble DL, Plummer J, et al. The prevalence of chronic bronchitis, chronic airway obstruction, and respiratory symptoms in a Colorado city. Am Rev Respir Dis 1971;103:209-228.
28. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: Data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-1689.
29. Lebowitz MD, Knudson RJ, Burrows B. Tucson epidemiologic study of obstructive lung diseases: I. Methodology and prevalence of disease. Am J Epidemiol 1975;102:137-152.
30. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey. 1996. Vital Health Stat 10, 1999;1-212. Available at: www.cdc.gov/nchs/data/series/sr_10/sr10_200.pdf. Accessed March 2006.
31. Mannino D. COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121:121-126.
32. Center for Medicaid and Medicare Services (CMS). Data compendium. Available at: www.cms.hhs.gov/DataCompendium/02_2003_Data_Compendium. asp#TopOfPage. Accessed April 2006.
33. Blackwell DL, Collins JG, Coles R: Summary health statistics for U.S. adults: National Health Interview Survey, 1997. Vital Health Stat 13, 2002;10:1-109.
34. Popovic JR, Kozak LJ: National hospital discharge survey: Annual summary, 1998. Vital Health Stat 2000;13:1-194.
35. Mapel DW, Hurley JS, Frost FJ, et al: Health care utilization in chronic obstructive pulmonary disease: A case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653-2658.
36. O'Brien JA, Ward AJ, Jones MKC, et al. Utilization of health care services by patients with chronic obstructive pulmonary disease. Respir Med 2003;97 (Suppl A):S53-S58.
37. Incalzi RA, Fuso L, Serra M, et al. Exacerbated chronic obstructive pulmonary disease: A frequently unrecognized condition. J Intern Med 2002;252(1):48-55.